"Grifols'cooperation in the USA represents a very positive step in the post-McKesson era for Health Robotics'products in America, giving our company access to an experienced, sizeable, and dedicated Sterile Compounding team. Furthermore, with the release of 1H2011 results next week, 2 additional key partnerships between Health Robotics with American companies will be announced, persisting on the McKesson-replacement strategy path" stated Gaspar DeViedma, Health Robotics' Executive Vice President.

About Grifols:

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since
May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. Grifols is the leading European plasma products company, and the fourth-largest producer in the world. The company plans to strengthen its position within the industry as a vertically integrated company, on the basis of its completed investments and its ongoing program for the period 2008-2012. In terms of raw material, Grifols has secure plasma supplies from its network of 80 plasmapheresis centers in the United States, while its production plants in
Barcelona (Spain) and
Los Angeles (United States) ensure that it has the fractionation capacity to satisfy rising demand. In addition, the company has implemented an ambitious investment plan to enable it to deliver sustained growth over the next 8 to 10 years. Grifols' Hospital Division focuses on research, development, manufacturing and marketing non-biological products used in hospitals, clinics and infusion centers. Grifols' Hospital Division products are designed to increase safety and efficiency in the hospital pharmacy. For more information, please visit http://www.grifols.com